ArticleSpinal cord2026
Nanoformulated fingolimod attenuates NLRP3 inflammasome activation and promotes functional recovery in a rat model of spinal cord injury.
Article in Spinal cord, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
STUDY
designAnimal study.
objectivesThe NLRP3 inflammasome is a key mediator in secondary cascade of spinal cord injury (SCI), making it a potential therapeutic target. This study aimed to develop a nanoformulated version of fingolimod and investigate its effects on neuroinflammation, NLRP3 inflammasome activity, glial activation, lesion volume, and functional outcomes in a rat model of moderate contusive SCI.
settingExperimental animal research laboratory, AlSafwa University College, Karbala, Iraq.
methodsFingolimod-loaded PLGA nanoparticles were synthesized using the emulsion solvent evaporation method and characterized for size, morphology, and drug release. Adult male Wistar rats underwent a standardized contusion SCI at T9 and were randomized into three groups (n = 13): Sham, SCI + Vehicle, and SCI + Nano-Fingolimod (10 ng/ml). Behavioral assessments using the BBB locomotor test were performed on days 1, 3, 5, 7, 10, 12, and 14 post-injuries. Histological analysis quantified lesion volume and inflammatory cell infiltration. Immunofluorescence (IF) and Western blotting were used to evaluate the expression of NLRP3, ASC, cleaved caspase-1, IL-1β, GFAP, and Iba-1.
resultsNano-fingolimod significantly improved BBB locomotor scores compared to the SCI group (p < 0.0001), indicating enhanced motor recovery. Histological examination revealed reduced lesion volume and inflammatory cell density in the treatment group. IF and Western blot analyses showed marked suppression of NLRP3 inflammasome signaling components (NLRP3, ASC, cleaved caspase-1, and IL-1β) and reduced glial activation (GFAP, Iba-1).
conclusionNanoformulated fingolimod provides neuroprotection and improves functional recovery after SCI by attenuating NLRP3 inflammasome activation and glial reactivity. Targeted nanodelivery enhances its CNS bioavailability and reduces toxicity, positioning it as a promising candidate for SCI therapy. SPONSORSHIP: None.
Indexed as
Identifiers
41723253What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.